Management of Hormone-Sensitive Metastatic Prostate Cancer

Neeraj Agarwal, Maha Hussain*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Targeting gonadal androgen synthesis (often in conjunction with blockade of androgen receptor) is the cornerstone of treatment of hormone-sensitive metastatic prostate cancer (HSPC). Despite the failure of androgen deprivation therapy, most tumors maintain some dependence on androgen or androgen receptor signaling for proliferation. This article reviews the current standard of care for metastatic HSPC, mechanisms of treatment resistance, novel drugs targeting the androgen signaling pathway, biomarkers predicting response to treatment and survival, future directions, and ongoing clinical trials in HSPC.

Original languageEnglish (US)
Pages (from-to)1221-1241
Number of pages21
JournalHematology/Oncology Clinics of North America
Issue number6
StatePublished - Dec 2013


  • Androgen signaling inhibitor
  • Future directions
  • Hormone-sensitive metastatic prostate cancer
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Management of Hormone-Sensitive Metastatic Prostate Cancer'. Together they form a unique fingerprint.

Cite this